Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

X4 Pharmaceuticals Announced New Clinical Data From Its Ongoing Phase 2 Trial Of Of Mavorixafor For Chronic Neutropenia, Showing Mavorixafor Was Generally Well Tolerated And Durably Increased Participants' Absolute Neutrophil Counts

Author: Benzinga Newsdesk | June 27, 2024 06:33am
  • 100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date.
  • Durable mean ANC levels above the lower limit of normal for CN were achieved for participants on mavorixafor monotherapy at Months 3 and 6.

Posted In: XFOR